Latest News

Therapeutics Acquisition Corp., Sponsored by RA Capital Management, L.P., Announces Closing of $135.7 Million Initial Public Offering, Including the Full Exercise of the Underwriter’s Option To Purchase Additional Shares

BOSTON–(BUSINESS WIRE)–Therapeutics Acquisition Corp. (Nasdaq: TXAC) (the “Company”) announced today that on July 10, 2020 it closed its initial public offering of 13,570,000 shares of Class A common stock, including 1,770,000 shares issued pursuant to the exercise by the underwriters of their over-allotment option. The offering was priced at $10.00 per share, resulting in gross proceeds of $135,700,000. The Company, sponsored by RA Capital Management, L.P., is led by Chairman and CEO Peter K

Source link

Related posts

STAT Plus: Pharmalittle: Trump’s ‘Buy American’ order raises doubts; Gilead looks to boost global remdesivir output


Jet Lag Remedies: Strategies To Minimize Symptoms


Two marine molecules show potential to treat Alzheimer's disease


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World